Study to Assess the Efficacy and Safety of Raxone in LHON Patients — LEROS

Leber's Hereditary Optic Neuropathy (LHON) Clinical Trial

Official title:
External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)

Status Completed

Clinical Trial Summary

LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leber's Hereditary Optic Neuropathy (LHON)
Optic Atrophy, Hereditary, Leber
Optic Nerve Diseases

Clinical Trial Details

NCT number	NCT02774005
Study type	Interventional
Source	Santhera Pharmaceuticals
Contact
Status	Completed
Phase	Phase 4
Start date	May 2016
Completion date	March 29, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02771379` - Post Authorisation Safety Study With Raxone in LHON Patients
Completed	`NCT02796274` - Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Recruiting	`NCT04912843` - Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy	Phase 2/Phase 3
Terminated	`NCT01389817` - Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)	Phase 1/Phase 2
Completed	`NCT05555784` - Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection